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“Everything will be alright in the end. If it is not alright, it is not yet the end.” 
(Unknown) 
 
 

   
ABSTRACT 
Placental transfer of maternal Ro/SSA and La/SSB autoantibodies during pregnancy is 
associated with conduction disturbances and inflammation in the developing fetal heart, termed 
autoimmune-mediated congenital heart block (CHB). Maternal Ro/SSA and La/SSB 
autoantibodies are the main risk factors associated with the fetal cardiac manifestations to date, 
however, the low recurrence rate despite persisting autoantibodies in subsequent pregnancies 
indicates that additional factors determine fetal susceptibility. The complex interactions 
between fetal genetic variants and factors that influence the intrauterine environment are 
thought to trigger or prevent the onset of CHB in Ro/SSA and/or La/SSB exposed pregnancies. 
The identification of such variants and factors was the main aim of this thesis.  
 
Genome-wide SNP association studies in families with at least one child affected by CHB 
and an anti-Ro52/SSA positive mother identified distinct cellular pathways associated with 
CHB. Exploration of potential candidate genes in the CHB-associated regions identified 
auxilin as a novel fetal susceptibility gene affecting cardiac excitation-contraction coupling. 
Discovery of additional CHB-associated variants affecting genes involved in vesicular or 
transmembrane transport and cardiac function further supported the idea that genetic variants 
in pathways connected to cardiac conduction and contractility may influence fetal 
susceptibility to disease. Furthermore, CHB-associated variants affecting genes with function 
assigned to immune responses emerged from our association studies and are likely to 
contribute to the inflammatory and tissue destructive processes connected with CHB. 
Ro/SSA autoantibodies are associated with interferon activation, and we found that 
cardiomyocyte expression of CHB-associated genes is affected by interferon-alpha stimulation. 
PBMCs from neonates with CHB and exposed to Ro/SSA autoantibodies in utero also 
displayed differential expression of several CHB-associated genes. Interestingly, expression of 
auxilin was altered in cardiomyocytes and PBMCs, validating the relevance of this particular 
gene and its pathway in CHB pathogenesis. We further identified and confirmed distinct class 
I and II HLA allele associations with CHB implementing potential impact for disease. Among 
the factors that may influence the intrauterine environment, we found that seasonal timing of 
pregnancy, infections, outdoor activity and psychological stress associated with the risk for 
CHB in Ro/SSA positive pregnancies. Finally, we also investigated potential cross-targets for 
the maternal anti-Ro52/p200 antibodies, and fetal intrauterine exposure to these maternal 
autoantibody specificities may further influence clinical outcomes of CHB. 
 
In summary, our data expands the current understanding of CHB pathogenesis, and suggests 
that the overall fetal susceptibility to CHB and degree of disease severity depends on a 
combination of genetic risk variants, their overall functional consequences, and their 
interactions with intrauterine factors in addition to the effect of fetal exposure to maternal 
Ro/SSA autoantibodies. 
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1 INTRODUCTION 
Placental transfer of maternal Ro/SSA and La/SSB autoantibodies during pregnancy is 
associated with conduction disturbances and inflammation in the developing fetal heart, termed 
autoimmune-mediated congenital heart block (CHB). Maternal autoantibodies are the main 
risk factor associated with the fetal cardiac disease to date, however, the low recurrence rate 
despite persisting autoantibodies in subsequent pregnancies indicates that additional factors 
determine fetal susceptibility to develop CHB. The complex interaction between fetal genetic 
variants and factors that influence the intrauterine environment is thought to trigger or prevent 
the onset of CHB in Ro/SSA and/or La/SSB exposed pregnancies. The identification and 
functional exploration of such variants and factors was the main aim of this thesis.  
 
 
1.1 AUTOIMMUNE DISEASES 
 
In autoimmune diseases, the loss of immunological tolerance to self-antigens causes 
destructive immune responses against self-tissues. Loss of control over immune-recognition 
and inflammation results in continuous immune activation, governed by periods with disease 
flares and those with quiescent disease (Valesini et al., 2015). Autoimmunity is considered to 
result from the complex interaction of genetic and environmental factors, and the common 
understanding of autoimmune disease pathogenesis is that disease is triggered by an 
environmental risk factor in genetically predisposed individuals (Colafrancesco et al., 2013).  
The observation that the incidence of autoimmune disease in selected families is increased 
together with a higher concordance for disease in identical twins compared to the risk in the 
general population has led to the conclusion of a genetic component involved in disease 
etiology (Becker et al., 1998). Genome-wide association studies (GWAS) have demonstrated 
that several genetic components in different loci contribute to the complex disease pathogenesis 
in sporadic cases with little risk contribution from each of the associated disease variants. The 
complexity of gene-gene interactions and epigenetics have made it further difficult to identify 
causal genetic components involved in autoimmune disease etiology (Lewis and Knight, 2012). 
However, it has also become obvious that most of the genetic associations related to 
autoimmunity reside within the MHC locus (Matzaraki et al., 2017). Genetic variants may 
overlap between several diseases; identifying general pathogenic mechanisms in autoimmune 
disease development e.g. break of tolerance. By contrast, associations with non-MHC loci have 
often been related to one or a specific group of autoimmune diseases. This is exemplified by 
tyrosine phosphatase PTPN22, involved in lymphocyte activation signaling or the STAT4 
transcription factor and their association with several systemic autoimmune diseases (Begovich 
et al., 2004; Bottini et al., 2004; Gregersen and Olsson, 2009; Kyogoku et al., 2004), while e.g. 
the IRF5 transcription factor polymorphisms associate with systemic lupus erythematosus 
(SLE) and Sjögrens´s syndrome (SS) (Graham et al., 2006; Miceli-Richard et al., 2007). 
Moreover, distinct MHC alleles are associated with the production of certain autoantibody 
profiles, typically of a distinct type of disease and mechanism of pathogenesis (Berg et al., 
2000; Morris et al., 2014; Ronnelid et al., 2017), while other MHC alleles, like HLA-DRB1*13 
are associated with a variety of autoimmune diseases and considered to mediate similar effects 
across these diseases (Lundstrom et al., 2009; Vasconcelos et al., 2009; Zeitlin et al., 2008). 
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Despite the identification of the genetic component contributing to autoimmune diseases, 
identical twins discordant for disease suggest that an environmental component is involved in 
disease etiology (Gregersen, 1993). Environmental factors such as infections, smoking, diet 
and seasonal variation pattern (e.g. representative of levels of vitamin D, exposure to ultraviolet 
light) have been shown to contribute to autoimmune diseases for instance in the context of 
type-1 diabetes, rheumatoid arthritis and multiple sclerosis (Morran et al., 2015; Padyukov et 
al., 2004; Willer et al., 2005). 
 
 
1.2 RHEUMATIC DISEASES IN MOTHERS OF CHILDREN WITH CHB 
 
Rheumatic autoimmune diseases are complex diseases and among others include systemic 
lupus erythematosus (SLE), Sjögren´s syndrome (SS), rheumatoid arthritis (RA) and as well 
as the less defined group of undifferentiated or mixed connective tissue disease (UCTD). 
These autoimmune diseases occur more frequently in women than men, and, among other 
diagnostic criteria, present with specific autoantibody profiles (Gleicher and Barad, 2007) 
(Lockshin et al., 2015). From several studies, it has become evident that discrete genetic 
variants within the MHC region are associated with the production of certain autoantibodies 
that can be either common for a certain group of autoimmune diseases or specific for a 
distinct disease (Lockshin et al., 2015; Matzaraki et al., 2017). HLA-DRB1*03 has been 
associated with the presence of Ro/SSA autoantibodies and placental transfer of these 
autoantibodies is in turn associated with an increased risk for the development of cardiac 
and/or non-cardiac manifestations of neonatal lupus erythematosus (NLE) in the child (Litsey 
et al., 1985; Loiseau et al., 2001; Scott et al., 1983). Commonly, the women carrying Ro/SSA 
autoantibodies are diagnosed with SLE and/or SS, and to a smaller proportion diagnosed with 
UCTD (Cavazzana et al., 2001; Chan and Andrade, 1992; von Muhlen and Tan, 1995). 
However, some women may be asymptomatic and without a diagnosis at the time of 
pregnancy despite positive autoantibody serology. Because of the association between 
maternal autoantibodies and fetal disease, NLE is also defined as a passively acquired 
autoimmune disease. 
Both SS and SLE are rheumatic diseases, affecting more women than men (ratio 9:1), 
and are characterized by B cell hyperactivity, production of autoantibodies, presence of an 
interferon signature and the increased risk for B lymphoma development (Bennett et al., 
2003; Gottenberg et al., 2006; Theander et al., 2006). SS is a relatively common disease 
affecting the exocrine salivary and lacrimal glands resulting in lymphocytic infiltrates and 
progressive tissue destruction, which causes dryness of the mouth and eyes (Jonsson et al., 
2000). The peak incidence of SS is women between 45 to 55 (Mavragani and Moutsopoulos, 
2010) but SS may also affect younger individuals, defining two disease subgroups, and 
autoantibodies have been described as more prevalent in early onset SS (Haga and Jonsson, 
1999). SLE is a more heterogenous disease and destructive processes are characterized by 
the deposition of immune complexes in a variety of organs including the kidneys, lungs, 
joints, skin and blood vessels and the central nervous system. Typically, SLE affects more 
women in their child-bearing years (Klippel, 1997; Petri, 2001). 
Pregnancy complications in women with autoimmune diseases, including SS and SLE, 
are more frequently observed than in healthy women, with increased risk for preeclampsia, 
perinatal death, preterm delivery and delivery of children small for gestational age 
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(Skomsvoll et al., 1998; Skomsvoll et al., 1999). Pregnancy management in SLE patients has 
improved; flares during pregnancy are mild and often require only minor treatment adaptions 
(Buyon et al., 2015; Tincani et al., 2006). However, renal flares associated with severe 
pregnancy complications as well as other complications still occur and hence patients require 
special care during pregnancy (Clowse et al., 2006; Yasmeen et al., 2001). SS is a 
considerably milder disease compared to SLE, with a slightly later mean time of disease 
onset, and less pregnancy complications are described for women diagnosed with SS, even 
if some studies report complications for this group of women (Haga et al., 2005; Hussein et 
al., 2011; Julkunen et al., 1995).  
 
 
1.3 NEONATAL LUPUS ERYTHEMATOSUS 
 
Neonatal lupus erythematosus (NLE) is a passively acquired autoimmune disease and presents 
with cardiac (CHB) and non-cardiac manifestations in individuals exposed to maternal Ro/SSA 
and La/SSB autoantibodies in utero. The population-based incidence of autoantibody-mediated 
CHB is 1 case in 23.000 live births (Skog et al., 2016).  
 
1.3.1 Non-cardiac manifestations 
Cutaneous lesions are one of the most common non-cardiac manifestations, present in 
approximately 15-25% of the infants with NLE (Buyon and Clancy, 2003b; Lee and Weston, 
1997). Hepatic and hematological aberrances are also included in the spectrum of non-cardiac 
manifestations, all of which are considered transient and resolve after the maternal 
autoantibodies are cleared from the infant´s circulation (Admani and Krakowski, 2013). 
Hepatic involvement is usually asymptomatic and presents with elevated liver enzymes 
(Silverman and Jaeggi, 2010). Incidence numbers vary across different studies and dependent 
on whether presented in combination with other manifestations range between 10-40% (Cimaz 
et al., 2003; Lee et al., 1993; Lee et al., 2002; Watson et al., 1984). Hematological abnormalities 
including neutropenia and thrombocytopenia have been described as additional non-cardiac 
manifestations of NLE with an incidence of 26% in a larger cohort study by Cimaz and 
colleagues (Cimaz et al., 2003; Watson et al., 1988; Wolach et al., 1993). Even though 
neurological and skeletal manifestations are reported among infants exposed to maternal 
autoantibodies, these are considered very rare conditions compared to the other non-cardiac 
manifestations (Boros et al., 2007; Nakayama-Furukawa et al., 1994; Shanske et al., 2007). 
 
1.3.2 Cardiac manifestations 
The most recognized cardiac manifestation in NLE is a third degree atrioventricular block 
(AVB) in the absence of major structural heart diseases, which develops when fibrosis and 
calcification replace the AV node (Buyon et al., 2009; Jaeggi et al., 2002). The majority of 
cases are diagnosed in utero between pregnancy weeks 18 to 24 or during the neonatal period 
(within 27 days postpartum) (Brucato et al., 2010; Hornberger and Al Rajaa, 2010). A third 
degree AVB is characterized by a complete block of signal conduction through the AV node 
resulting in a slow ventricular rate (Figure 1). 
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Figure 1. Signal transmission in a normal heart and a heart presenting with an atrioventricular block. 
 
Congenital AVB is also present in congenital heart diseases with structural malformations 
involving the AV node. This group represents the other major etiology of AVB detected in 
utero (Hitz et al., 2012; Preuss and Andelfinger, 2013; Zaidi and Brueckner, 2017). Of note, 
mitochondrial diseases are common and often associate with cardiac diseases including heart 
block, e.g. primary mitochondrial cardiomyopathy (Andersson et al., 2011). Arrhythmogenic 
right ventricular cardiomyopathy (ARVC) is an example of another disease etiology apart 
from CHB, where cardiac injury may be accompanied by an inflammatory response and 
repair mechanisms resulting in tissue remodeling contribute to pathophysiology (Svensson 
et al., 2016). 
There is increasing evidence that CHB comprises a broader spectrum of fetal cardiac 
manifestations affecting both the cardiac conduction system and the myocardium. This 
evidence comes in part from centers with surveillance of risk pregnancies where it has been 
recognized that the bradycardia is preceded and paralleled by additional cardiac pathologies 
(Brucato et al., 2010; Hornberger and Al Rajaa, 2010). In early stages of CHB, these 
manifestations include sinus node dysfunction, lower degree atrioventricular block and a 
prolonged isovolumetric contraction time (ICT) and approximately one third of the cases are 
affected by these potentially reversible conditions (Bergman et al., 2009; Kurita et al., 1992; 
Sonesson et al., 2004). More diverse myocardial manifestations including myocardial 
inflammation, have been observed in 15-20% of the fetuses before birth (Jaeggi et al., 2002; 
Moak et al., 2001) and nearly one-third of the fetuses show signs of junctional ectopic or 
ventricular tachycardia (Villain et al., 2006; Zhao et al., 2008). Endocardial fibroelastosis and 
dilated cardiomyopathy (DCM) are the most severe manifestations and associate with a high 
mortality rate in the fetus (Hornberger and Al Rajaa, 2010). Of note, a late-onset DCM may 
also occur, but this disease entity is considered different compared to the in utero or neonatal 
DCM (Morel et al., 2017). 
In this thesis, CHB refers to the spectrum of fetal cardiac manifestations occurring in 
neonatal lupus.  
 
 
1.3.2.1 Incidence, recurrence rate and mortality 
Complete congenital heart block in the general population is rare, with 1 case in 15,000-20,000 
live births (Michaelsson and Engle, 1972; Siren et al., 1998). Among fetuses exposed to 
maternal Ro/SSA autoantibodies, the incidence for a third degree AV block is increased, and 
ranges between 1-2% (Ambrosi et al., 2012b; Brucato et al., 2010; Buyon et al., 2015; Morel 
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et al., 2017). In anti-Ro52/SSA positive women, the prevalence of CHB has been suggested to 
be even further increased (Buyon et al., 1998; Salomonsson et al., 2002). The recurrence rate 
of third degree AVB in following pregnancies is notable, but far from 100%, and ranges 
between 12-18% despite persisting maternal autoantibodies, thus indicating that additional 
factors influence disease outcome in the exposed fetuses (Buyon et al., 1998; Salomonsson et 
al., 2011; Solomon et al., 2003). 
In anti-Ro52/SSA antibody positive pregnancies approximately 30% of the fetuses present 
with signs of first degree AVB, which most often spontaneously reverts before birth (Sonesson 
et al., 2004). Even though validated numbers for incidence of lower degree of AV block in 
newborns are still under investigation, the incidence of first degree AV block ranges between 
3-14% in Ro/SSA exposed fetuses (Bergman et al., 2009; Friedman et al., 2008; Rein et al., 
2009). In a recent study, Sonesson and colleagues could show that the recurrence rate of 
conduction disturbances in anti-Ro/SSA antibody exposed fetuses is higher than previously 
described when taking also milder forms of block into account (Sonesson et al., 2017). The 
mortality in complete AVB is high, ranging between 15-25% (Eliasson et al., 2011; Eronen et 
al., 2000; Izmirly et al., 2011; Jaeggi et al., 2002; Sharland et al., 1991).  
 
 
1.3.2.2 Maternal Ro/SSA and La/SSB autoantibodies and CHB 
The association between maternal Ro/SSA and La/SSB autoantibodies and NLE in the 
offspring is known since more than 30 years (Scott et al., 1983; Taylor et al., 1988). The 
Ro/SSA antigen complex refers to Ro52 and Ro60, two non-homologous proteins named after 
their mass in kilo Dalton (kD). The Ro52 protein consists of four functional domains, an N-
terminal RING, a B-box, a coiled-coil domain and a C-terminal B30.2 region and belongs to 
the family of tripartite proteins (TRIMs) (Reymond et al., 2001). As other TRIM family 
proteins, Ro52 (TRIM21) has intrinsic E3 ligase activity and functions in the cellular process 
of ubiquitination (Espinosa et al., 2006), a posttranslational modification for proteasomal 
degradation and intracellular signaling (Swatek and Komander, 2016). Ro52 is predominantly 
expressed in immune cells and organs and plays an important role in innate and anti-viral 
responses as well as cell proliferation, survival or death (Espinosa et al., 2006; Kong et al., 
2007). Ro60 is an ubiquitously expressed protein binding small cytoplasmic RNAs, hYRNAs. 
Further, Ro60 has been shown to bind misfolded non-coding RNAs and is important for cell 
survival after ultraviolet irradiation (Chen et al., 2000; Chen et al., 2003). The La/SSB antigen 
consists of the 48kDa La protein and like Ro60, associates with hYRNA complexes with a 
suggested function in transcriptional termination and virus replication (Wolin and Cedervall, 
2002). 
Even though the association between CHB and maternal antibodies directed towards the 
Ro52, Ro60 and La autoantigens varies across studies, the majority of maternal autoantibodies 
target the Ro52 protein, present in almost 95% of the mothers to CHB-affected individuals 
(Buyon and Clancy, 2003a; Eronen et al., 2004; Fritsch et al., 2006; Julkunen et al., 1993; 
Salomonsson et al., 2002; Sonesson et al., 2017). However, a clear distinction between Ro52 
and Ro60 antibody associations has been difficult because of their common co-occurrence, and 
the individual impact on the development of CHB for the respective antibody is still a matter 
of debate. The relevance of anti-La antibodies for the development of CHB is controversially 
discussed and while it was associated with cutaneous NLE rather than CHB (Jaeggi et al., 2010; 
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Silverman et al., 1995), Gordon and colleagues reported that anti-La antibodies increased the 
risk of CHB in their study population (Gordon, 2004).  
The tight association between CHB and maternal anti-Ro52 antibodies, and the 
identification of immunodominant epitopes within the Ro52 protein have prompted studies 
assessing the fine specificity of anti-Ro52 antibodies associated with CHB (Kato et al., 1995; 
Pourmand et al., 1998). Fritsch and colleagues identified several dominant epitopes within the 
Ro52 protein in their study cohort representative of specificities in SLE mothers (Fritsch et al., 
2006). Epitope mapping in a study cohort with mainly SS or asymptomatic mothers revealed 
CHB association with maternal antibodies directed towards amino acids 200-239 of Ro52, 
denoted p200 (Ottosson et al., 2005; Salomonsson et al., 2002; Strandberg et al., 2008). The 
relevance of the p200 epitope was further validated in a prospective study where higher titers 
of Ro52/p200 antibodies were correlated with longer AV time in the fetus during the risk period 
of CHB (Salomonsson et al., 2005). The pathogenic effect of the anti-Ro52 and anti-
Ro52/p200 antibodies has been further evidenced by in vivo studies showing transfer of these 
specific antibodies into pregnant rats induced AVB in the offspring (Ambrosi et al., 2012a; 
Strandberg et al., 2010). 
 
 
1.3.2.3 Autoantibody cross-target hypothesis and CHB pathogenesis  
Despite the association between CHB and maternal anti-Ro/SSA autoantibodies, the 
mechanisms by which the maternal autoantibodies mediate their pathogenic effects are not 
fully understood, specifically considering the low cardiac expression of Ro52 as well as its 
intracellular localization (Espinosa et al., 2009; Espinosa et al., 2006). Related to this, it has 
been postulated that anti-Ro52/p200 antibodies cross-react with other proteins expressed on 
the plasma membrane of fetal cardiac cells causing electrophysiological disturbances. In 
support of this hypothesis, in vitro studies demonstrated direct binding of maternal 
Ro52/p200 antibodies caused disturbances in the calcium homeostasis and subsequent 
apoptosis in cultured rat cardiomyocytes (Salomonsson et al., 2005). Identification of cardiac 
L-Type and T-Type calcium channels as potential cross-targets for maternal anti-Ro52/p200 
antibodies and functional impairment of these channels in presence of maternal 
autoantibodies further supported this hypothesis (Boutjdir et al., 1997; Karnabi et al., 2011; 
Qu et al., 2005; Qu et al., 2001; Strandberg et al., 2013). The Cav1.3 channel is one example 
for a potential cross-target identified, and the IgG fraction of antibodies purified from 
Ro/SSA positive mothers of children with CHB inhibited the Cav1.3 calcium channel which 
the authors hypothesize could account for the sinus bradycardia and contractile impairment 
seen in human CHB (Qu et al., 2005). Another suggested cross-target for maternal 
autoantibodies is the cardiac 5-HT4 serotoninergic receptor (Eftekhari et al., 2001), although 
no association between presence of these maternal cross-reactive autoantibody specificities 
and fetal CHB was detected (Buyon et al., 2002). A recent study identified several discrete 
epitopes of Ro52/p200 that associated with fetal cardiac conduction system manifestations 
in rodents, further suggesting that several different antibody specificities and cross-targets 
may exist and contribute to pathogenic mechanisms related to CHB (Hoxha et al., 2016) 
The severe cardiac manifestations during CHB pathogenesis are preceded or paralleled 
by sustained inflammation of the conductive system and/or myocardium (Friedman et al., 
2003). This has been evidenced by the presence of proinflammatory cytokines, leukocyte 
recruitment, IgG and complement deposition in cardiac histopathology sections from 
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deceased CHB fetuses who had been exposed to maternal Ro/SSA autoantibodies (Clancy et 
al., 2004; Nield et al., 2002a). Related to this, it has been hypothesized that the inflammatory 
processes are partly driven by the activation of macrophages through the engulfment of 
Ro/SSA immune complexes on apoptotic cardiocytes and subsequent recruitment of 
leukocytes and production of proinflammatory cytokines (Clancy et al., 2004; Miranda-Carus 
et al., 2000). Moreover, fibrosis and calcification of the AV node have been described in 
relation to a third degree AVB as well as endocardial fibroelastosis all part of the spectrum 
of cardiac manifestations in affected fetuses, and a crosstalk between fibroblast and 
macrophages has been implicated to drive these tissue destructive processes during 
pathogenesis  (Briassouli et al., 2011; Brito-Zeron et al., 2015; Clancy et al., 2004; Friedman 
et al., 2003). Even though this suggests that leukocyte infiltration, fibrosis accompanied by 
TGF-β upregulation and subsequent scar tissue formation are part of the inflammatory and 
fibrotic cardiac injuries during autoimmune-mediated CHB pathogenesis, the functional 
mechanism related to the maternal Ro/SSA autoantibodies is not fully understood, especially 
considering the fast course of destructive processes during disease pathogenesis. Surveillance 
programs have indeed shown that individuals can progress from a normally presenting heart to 
an advanced block within a matter of days (Friedman et al., 2009). 
 
 
 
Figure 2. Two-phase model for CHB development (Ambrosi and Wahren-Herlenius, 2012).  
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Collectively the above-mentioned results gave rise to the two-phase model for CHB 
pathogenesis (Figure 2), where cross-reactive maternal autoantibodies induce conduction 
abnormalities observed as lower degree AVB, and further dysregulation of the conductive 
system and uncontrolled apoptosis followed by leukocyte infiltration, inflammation, fibrosis 
and calcification eventually lead to permanent damage to the fetal heart (Ambrosi and 
Wahren-Herlenius, 2012). However, while this current model explains some of the direct 
effects of maternal autoantibodies in fetal cardiac pathogenesis, it does not fully explain why 
some fetuses with milder CHB progress to a more severe CHB while others revert to a normal 
heart function despite continuous exposure to maternal autoantibodies. 
 
 
1.3.2.4 Risk factors and susceptibility to CHB 
The low recurrence rate of CHB in subsequent pregnancies despite persistent maternal Ro/SSA 
autoantibodies indicates that additional factors influence fetal susceptibility to CHB. 
Genetic polymorphisms influencing fetal susceptibility to CHB upon exposure to maternal 
Ro/SSA autoantibodies have been reported in a candidate gene approach and a genome-wide 
association study (Clancy et al., 2003; Clancy et al., 2010) showing significant associations 
within the 6q21, 21q22 genomic locations and within the TGF-beta gene locus. While these 
data indicate fetal genetic factors may be additional factors influencing fetal susceptibility 
related to CHB, these data still require confirmation. Moreover, one may also be cautious in 
the interpretation of case control studies in the context of CHB. Comparing frequencies among 
cases and population-based controls is likely to reflect the maternal disease variants as mothers 
to CHB cases may have SLE or SS, or even if asymptomatic, are genetically different from the 
general population. Nevertheless using congenic rat strains, Strandberg and colleagues further 
supported the hypothesis that fetal MHC and non-MHC genes determine susceptibility to CHB 
in exposure to autoantibody specificities encoded by the maternal MHC (Strandberg et al., 
2010). 
Apart from genetic factors influencing fetal susceptibility to CHB, other risk factors 
including maternal age and hypothyroidism, season of birth and hypoxia have been described 
(Ambrosi et al., 2012a; Askanase et al., 2006; Clancy et al., 2007; Sonesson et al., 2017; Spence 
et al., 2006). On the contrary, fetal gender, parity and maternal disease activity did not emerge 
as risk factors associated with CHB (Ambrosi et al., 2012b; Buyon et al., 1998; Eronen et al., 
2004; Llanos et al., 2009; Solomon et al., 2003). 
 
 
1.3.2.5 Surveillance and in utero treatment/prevention of CHB 
Surveillance programs to assess fetal cardiac function during the risk period for CHB (weeks 
18 to 24) have been developed (Friedman et al., 2009; Sonesson et al., 2017). For fetal 
surveillance, several methods can be used including echocardiography, electrocardiography 
and magnetocardiography whereof fetal echocardiography, using m-mode and Doppler are the 
most commonly used techniques. (Brito-Zeron et al., 2015). Additionally, hand-held Doppler 
devices have also been introduced for home monitoring. In addition to the better understanding 
of the spectrum of fetal cardiac manifestations, this has also led to earlier and potentially more 
efficient treatment and better fetal outcomes. This is important as a third degree AVB may 
develop in a matter of days from a normally presenting heart (Friedman et al., 2009) and to 
date no effective therapy exists (Brito-Zeron et al., 2015). 
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In utero treatment options have been tested to improve fetal outcomes and include anti-
inflammatory treatment using steroids, and transplacental treatment with fluorinated steroids 
(betamethasone and dexamethasone) (Bierman et al., 1988; Jaeggi et al., 2004). Betamimetics 
can be used to increase the fetal heart rate and myocardial output (Hutter et al., 2010; Jaeggi et 
al., 2004), however, as steroids are associated with risks for the mother and the developing 
child, treatment options should be well justified (Hutter et al., 2010; Tincani et al., 2006). 
Injection of intravenous immune globulins (IVIG) and plasmapheresis have also been used in 
treating CHB. Evidence-based treatment is however still lacking (Kaaja and Julkunen, 2003; 
Makino et al., 2007; Ruffatti et al., 2012).  
 
 
1.3.2.6 Postnatal outcomes in CHB 
Even though the majority of patients diagnosed with complete CHB require a pacemaker 
implant shortly after birth (Brito-Zeron et al., 2015; Eronen et al., 2000), postnatal outcomes in 
these individuals are very good, with a survival rate of 96% at follow-up after approximately 9 
years of pacing (Eliasson et al., 2015). This is concordant with a previous study reporting 
survival rates around 95% using similar follow-up intervals (Villain et al., 2006). Low birth 
weight with catch-up before pre-teen years and attention deficits in children exposed to 
maternal Ro/SSA autoantibodies in utero are outcomes reported, however it should be noted 
that the vast majority of children, despite their serious heart condition, do well during childhood 
and teen-years (Skog et al., 2013a; Skog et al., 2013b). 
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2 AIMS 
Fetuses exposed to maternal Ro/SSA autoantibodies are at risk to develop CHB. However, 
despite persisting autoantibodies in subsequent pregnancies, the recurrence rate for 
autoimmune-mediated CHB ranges between 12-18% suggesting that additional factors other 
than the maternal autoantibodies influence risk for CHB development.  
The aim of this thesis was to identify such additional risk factors for CHB, focusing on fetal 
genetic variants and environmental and lifestyle factors that the mother was exposed to or 
experienced during pregnancy. Specifically, the following aims were set: 
• To identify genetic polymorphisms associated with CHB in a genome-wide manner 
• To identify MHC alleles associated with CHB 
• To understand the influence of maternal body mass index, pregancy weight gain, 
seasonal timing of pregnancy, infections, sun exposure, outdoor activity and stressful 
events on the risk of CHB 
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3 METHODOLOGICAL CONSIDERATIONS 
In this section, the strategies to identify genetic and environmental risk factors related to 
autoimmune-mediated CHB and the screening approach for maternal cross-reactive 
autoantibodies will be discussed. 
 
 
3.1 CASES, FAMILIES AND CONTROLS INCLUDED IN THE THESIS 
 
To have a homogenous study population, we used strict inclusion criteria with regard to 
maternal serology and fetal cardiac manifestations to exclude confounding through sample 
heterogeneity.  
A Swedish cohort of families collected in a population-based manner with at least one 
child affected by CHB and a mother tested positive for Ro/SSA autoantibodies was the basis 
for initial risk factor studies and is described within Papers I, III, V and VI.  Families with 
individuals who had died from CHB at the time of DNA collection were not included, as DNA 
could not be retrieved from the case.  
European families with at least one child affected by CHB and a mother tested positive 
for Ro/SSA autoantibodies were identified and collected through collaborations with pediatric 
cardiologists and rheumatologists at several centers in Finland, Norway and Italy, and are 
described in Paper II and IV. 
 
 
3.2 STUDY DESIGN AND ANALYSIS STRATEGIES FOR GENETIC 
ASSOCIATIONS   
 
The mothers of individuals with CHB carry Ro/SSA autoantibodies and are commonly 
diagnosed with SLE or SS, and are genetically different from the general population (Gateva 
et al., 2009; Lessard et al., 2013). With a 50% chance of the fetus to inherit either of the two 
alleles of a specific gene from the mother, a deviation from the normal population will present 
in the offspring regardless of CHB or not. Hence an analysis of allele frequency differences 
between CHB cases and unrelated controls could not be used to identify genetic risk variants 
for CHB. Therefore, we chose a trio design for the genetic analyses, which includes the parents 
and affected offspring and uses the transmission disequilibrium test (TDT) which surpasses 
this problem (Spielman and Ewens, 1996). In complementary analyses approaches, we also 
used family-based association for disease trait (DFAM) and pedigree-disequilibrium test (PDT) 
(Laird et al., 2000; Purcell et al., 2007), allowing inference of missing parental genotypes using 
unaffected sibling genotypes.  
 
 
3.3 HLA-ASSOCIATION ANALYSIS 
 
Two approaches for HLA typing were used in the papers included in this thesis. In Paper III, 
PCR-based HLA typing was used for identification of HLA-A, -C and -DR alleles. Based on 
our findings, and with an extended European CHB family cohort, we used imputation of HLA-
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A, -B, -C and -DP, -DQ and -DR alleles based on microarray SNP data in Paper IV. The in 
silico imputation approach (Dilthey et al., 2016) was used to receive higher resolution HLA-
allele types to further fine map causal variants related to CHB, in a time and cost effective 
manner compared to the classical wet lab HLA genotyping approach. Correct HLA allele 
designation was ascertained by inclusion of Swedish reference genotypes for the class II region 
(Zhao et al., 2016) and by confirming alleles according to the Mendelian laws of inheritance in 
nuclear families. 
 
 
3.4 PROCEDURES IN GENERATING THE QUESTIONNAIRES  
 
Three approaches were employed for generating the specific questions included in the 
questionnaire used to identify maternal environmental and lifestyle factors influencing the risk 
of CHB. These included semi-structured interviews performed with mothers of children with 
CHB (Tingstrom et al., 2010; Tingstrom et al., 2013), data from our or others previous 
publications on potential risk or protective factors related to CHB (Ambrosi et al., 2012b; 
Izmirly et al., 2012) and an extract of questions previously used for risk factor investigation in 
rheumatoid arthritis and multiple sclerosis (Handel et al., 2010; Ilar et al., 2017). There were 
controlled case questions, statements to which the answer was given in a four-graded scale 
from totally agree to totally disagree, and open-ended questions to which specific comments 
could be added and space was provided for adding optional extra information. The 
questionnaires were validated in a test group before use.  
Recall bias related to the retro-perspective design is a limitation of the questionnaire-
related results. However, memories from pregnancy and delivery are often described as well 
remembered by mothers (Simkin, 1991) and the comparison of risk factors is between different 
pregnancies resulting in children with or without CHB from the same mothers possibly leading 
to even distribution of the remaining limitation between the two outcome groups. 
 
 
3.5 CROSS-REACTIVE TARGETS FOR MATERNAL AUTOANTIBODIES 
 
A few cross-reactive targets for maternal autoantibodies in CHB have been suggested (Boutjdir 
et al., 1997; Strandberg et al., 2013; Xiao et al., 2001). To expand the smaller scale cross-target 
approaches used in previous studies, we used a whole proteome peptide library to screen for 
additional cross-targets of Ro52/p200 autoantibodies (Paper VI). A limitation of our study is 
the peptide length (12-mers, 6 amino acid overlap), as target epitopes may require direct 
contribution from distant amino acids or longer stretches of the protein chain to fold correctly.  
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4 RESULTS AND DISCUSSION 
 
 
4.1 GENETIC VARIANTS AFFECTING CARDIAC SIGNAL TRANSMISSION AND 
CONTRACTION 
 
4.1.1 Genes with function in vesicular transport 
Overall, cardiac function is dependent on the electrical signal initiation and propagation as well 
as its subsequent conversion into mechanical contraction. The correct temporal and spatial 
distribution and function of the proteins and structural elements involved in this complex 
process is crucial for the rhythmicity of heartbeats. Thus, genetic variants of components that 
are part of these tightly regulated processes may have pathological consequences. In CHB, 
prolonged fetal AV-time and ICT are among the major cardiac manifestations observed, 
suggesting that impairment of the excitation-contraction coupling may be involved in CHB 
pathology (Bergman et al., 2009; Sonesson et al., 2004). Vesicular transport is a crucial cellular 
pathway for excitation-contraction coupling (Nori et al., 2004), and was one of the CHB 
associated pathways we identified (chapter 4.1). Therefore, one focus in the course of our 
studies was to identify and functionally explore genes in vesicular pathways. These are 
described and discussed in the following chapters. 
 
4.1.1.1 Auxilin is a fetal susceptibility gene for CHB with function in vesicular 
transport 
Several SNPs within the chromosomal region 1p31.3 associated with CHB. The verified top 
SNP (rs1570868, PGAWS=3x10-5, Paper I) is located in an intronic region of the 
DNAJC6/auxilin gene locus which made this gene a very interesting candidate gene to further 
investigate in the context of CHB. Additional information on the function of auxilin, the protein 
encoded by DNAJC6, in vesicular transport (Scheele et al., 2001) and association of the risk 
SNP with cardiac-specific expression differences (Paper I) further strengthened that 
DNAJC6/auxilin is a relevant candidate gene in the context of CHB. Of note, no other cardiac 
eQTL effect was observed among the genes investigated within the chromosomal interval 
1p31.3 (Paper I). Interestingly, we found that cardiac auxilin expression levels were high 
during fetal development, both before and during the risk period for CHB, and are decreased 
in adult cardiac tissue (Paper I). Moreover, among the fetal tissues tested, fetal cardiac 
expression is higher compared to expression levels in skeletal muscle or kidney (Paper I). 
Based on these results, we chose DNAJC6/auxilin as a novel fetal candidate gene for 
subsequent functional exploration. 
While auxilin was expressed both in the myocardium and conduction system of the human 
fetal heart, subcellularly auxilin co-localized with clathrin in a vesicular pattern in human fetal 
cardiomyocytes (Paper I). This indicates that auxilin function in the heart is also within 
clathrin-mediated vesicular transport, a function for this protein previously described in other 
cell types (Scheele et al., 2001).  
Association between cardiac auxilin expression and the CHB risk variant (rs1570868) 
suggested that the cardiac phenotype in CHB may lead to decreased protein levels. Therefore, 
we used auxilin-deficient mice as a disease model to further study the impact of auxilin for 
cardiac function in the context of CHB. After confirmation of auxilin expression in the heart 
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of wild-type pups, we assessed the impact of auxilin-deficiency on cardiomyocyte function. As 
Ca2+ is one of the main regulators of cardiomyocyte function, we evaluated spontaneous Ca2+ 
oscillations in primary cultures of wild-type and auxilin knockout neonatal cardiomyocytes. 
Compared to wild-type cells, auxilin-deficient cardiomyocytes showed decreased mean 
frequencies of Ca2+-transients over time in combination with an increased coefficient of 
variation, which was indicative of an overall disturbed cellular calcium homeostasis (Paper I). 
Moreover, we found impaired cardiac cell connectivity and communication with cells at greater 
distance comparing auxilin-deficient and wild-type cardiomyocytes in culture (Paper I).  
Given the described function of auxilin in clathrin-mediated endocytosis (Scheele et al., 
2001) and the finding that auxilin-deficient cardiomyocytes displayed a disturbed calcium 
homeostasis, we hypothesized that absence of auxilin may impair the recirculation of calcium 
channels to the plasma membrane of cardiomyocytes. We therefore compared plasma 
membrane expression of the calcium channel Cav1.3 in auxilin wild-type and knockout 
cardiocytes as a functional measure for intracellular recirculation. Flow cytometry revealed that 
mouse neonatal Sirpa+ cardiocytes (Dubois et al., 2011) had proportions of cells expressing 
Cav1.3 comparable in auxilin-deficient and wild-type mice, however Cav1.3 cell surface 
expression was significantly lower in Sirpa+Cav1.3+ auxilin-deficient cells compared to wild-
type cardiocytes (Paper I). Interestingly, cardiac expression levels of Cav1.3 RNA transcripts 
were significantly higher in auxilin-deficient neonatal cardiocytes compared to wild-type 
cells (Paper I). This indicates that decreased Cav1.3 expression on the plasma membrane of 
auxilin-deficient cells was not due to a general decrease in gene expression, and further 
suggests that auxilin-deficient cardiomyocytes upregulate the transcription of Cav1.3 to 
compensate for decreased protein levels on the cell surface.  
Functional relevance for fetal cardiac auxilin in the context of CHB was further 
supported by results from the analysis of Doppler profiles of mouse pups in utero. We found 
that auxilin-deficient pups in utero displayed several different CHB-related cardiac 
pathologies, including both prolonged AV-time and ICT, abnormal heart rate and arrhythmias 
including atrial and ventricular ectopic beats (Paper I).  
Auxilin is involved in clathrin-mediated endocytosis (Scheele et al., 2001) and absence of 
auxilin may thus impair the recirculation of ion channels or other molecules important for 
cardiac function to the plasma membrane of cardiomyocytes. Cav1.3 is important for excitation 
of cardiac pacemaker cells and subsequent propagation of the signal resulting in contraction-
coupling of ventricular cardiocytes (Mangoni et al., 2003) and our results indicated that absence 
of auxilin results in decreased surface expression of Cav1.3 that in turn may impact on the 
overall cardiac function. Decreased cell surface expression of ion channels, including Cav1.3, 
in absence of auxilin could also explain the lower cellular connectivity and communication and 
the decreased and less well-coordinated Ca2+ oscillations in auxilin-deficient cardiomyocytes 
in culture. Interestingly and in relation to our results, Cav1.3-deficient mice display a pattern 
of cardiac abnormalities with sinus bradycardia and AV block before birth (Karnabi et al., 
2011; Platzer et al., 2000), suggesting that decreased expression of Cav1.3 on the surface of 
auxilin-deficient cells may contribute in part to the cardiac abnormalities we observed in 
auxilin-deficient mice in utero.  
Fetuses exposed to maternal Ro/SSA autoantibodies have an increased risk to develop 
CHB (Buyon et al., 1989). Calcium channels, including Cav1.3, have been evidenced as 
potential cross-targets for the maternal Ro/SSA autoantibodies  and binding of these 
autoantibodies to their antigens expressed by cardiomyocytes inhibited calcium currents inflow 
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and led to disturbed calcium homeostasis and apoptosis (Karnabi et al., 2011; Qu et al., 2005; 
Salomonsson et al., 2005; Strandberg et al., 2013). Hence binding of the maternal 
autoantibodies may additionally affect calcium channel function, blocking and further 
disrupting the cardiac electrical-excitation coupling. This functional link can therefore explain 
why genetically predisposed individuals, carrying the auxilin variant, may be more susceptible 
to CHB in exposure to maternal autoantibodies in utero.  
Notably, in fetal cardiomyocytes, the sarcoplasmic reticulum is not yet fully developed, 
and thus excitation-contraction coupling mainly relies on plasma membrane calcium channels 
at the cell surface (Brillantes et al., 1994; Fisher, 1995). This is reversed in adult 
cardiomyocytes, where calcium is mainly released from sarcoplasmic reticulum stores. Hence 
decreased expression of auxilin accompanied by lower surface expression of calcium channels 
affects the function of fetal cardiomyocytes to a larger extent than adult cells, rendering the 
fetal heart more susceptible to the pathogenic effects of the maternal autoantibodies. This can 
explain why cardiac manifestations similar to CHB, despite persisting maternal autoantibodies 
are not observed in mothers to CHB affected individuals.  
Collectively, our data support auxilin as a novel and relevant fetal susceptibility gene for 
CHB with direct impact on fetal cardiac function through the vesicular transport pathway.  
 
 
4.2 HLA ASSOCIATIONS 
Results from the GWAS and pathway analyses revealed several SNP variants close to genes 
with function in immune response associate with CHB (Paper I and II). The association 
between the MHC locus and autoimmune diseases, including the rheumatic disease of the 
mothers of the CHB-affected individuals is well-established (Shiina et al., 2004). Together with 
results from animal studies demonstrating that fetal MHC genes are additional risk factors to 
exposure to maternal Ro/SSA autoantibodies (Strandberg et al., 2010), we aimed to identify 
human fetal MHC genes contributing to immune responses influencing fetal susceptibility to 
CHB.  
Parent-offspring trio analysis using PDT in individuals of the Swedish CHB family cohort 
(n=83 families) showed association of seven SNP markers with CHB in the extended MHC 
region (P<0.01, Paper III). HLA-allele typing in Swedish families (Paper III) and HLA allele 
imputation in the Swedish and international families (n=170, Paper IV) revealed protective 
associations of HLA-Cw*06 (P=0.03 Paper III and P=0.003 Paper IV) and HLA-DRB1*13 
(P =0.04 Paper III and P=0.007 Paper IV) alleles across both study approaches. An HLA-
DRB1*04 association with CHB (P=0.03) was identified in Paper III but could not be 
validated by the joint analysis approach (Paper IV).  
The expansion of MHC gene loci included in Paper IV identified novel suggestive 
associations for HLA class II genes with DQA1 and DQB1 alleles. Furthermore, the study 
revealed two novel haplotype associations with CHB, the protective DRB1-DQA1-DQB1 13-
01:03-06:03 (P=0.025) and the susceptible DRB1-DQA1-DQB1 08-04:01-04:02 (P=0.022) 
haplotype and those include some but not all of the CHB-associated and suggestively 
associated suballeles (Paper IV). Of note, no CHB-associations were observed for HLA-A, 
-B, -DPA1, -DPB1 and -DRB3, -B4 or -B5 alleles (Paper IV). 
Even though we observed CHB associations within the MHC region, these associations 
were less significant compared to the non-MHC associations revealed from Paper I and II. 
This is in contrast to study results from Clancy and colleagues showing a strong association 
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signal within the MHC locus (Clancy et al., 2010). However, in relation to the specific maternal 
genetic predispositions it is more likely these results reflect the maternal disease traits rather 
than the CHB-unique traits. Consistent with the maternal predisposition in the HLA region and 
the well-known HLA-DRB1*03 allele associations with SS and SLE and the production of 
Ro/SSA autoantibodies, we find significantly higher frequencies of HLA-A*01 (52%; P< 
3x10-6), HLA-Cw*07 (84%; P< 5x10-6) and class II HLA-DRB1*03 (79%; P< 3x10-29) and 
HLA-DRB1*11 (14%; P< 1x10-8) alleles, compared to the allele distribution in the general 
population and concordant to previous reports (Alexander et al., 1989; Miyagawa et al., 1997; 
Miyagawa et al., 1998) (Paper III). Intriguingly, the HLA alleles we found associated with 
CHB in the offspring of these mothers were different from the alleles associated with the 
maternal disease (Paper III and IV) and all associated variants passing thresholds for multiple 
testing conferred protective effects. We therefore conclude that certain fetal MHC alleles 
determine susceptibility to the effects of the maternal Ro/SSA antibodies in relation to the 
destructive immune responses during CHB pathogenesis. However, these fetal MHC alleles 
are different from the maternal alleles that are associated with the ability to generate the 
pathogenic antibodies.  
The class I HLA-Cw*06 allele was one of the most robust MHC associations with CHB 
identified in our study cohorts. HLA-C molecule:peptide complexes are potent inducers of 
cytotoxic responses through the interaction with receptors expressed by NK and CD8+ T cells  
(Blais et al., 2011). In connection to this, it is interesting that one of these effector cells, CD8+ 
T cells, are among the mononuclear cells infiltrating the fetal heart evidenced from 
immunohistology sections of CHB hearts (Nield et al., 2002a; Nield et al., 2002b). This 
indicates that MHC class I peptide presentation by certain allelic variants of the HLA-C 
molecule may be involved in disease pathogenesis. Moreover, these fast and specific cytotoxic 
effector functions are concordant with reports from centers with surveillance programs for 
pregnant Ro/SSA positive women reporting that severe degree heart block development from 
a normal appearing heart occurs within days (Friedman et al., 2009). A certain group of HLA-
C alleles, sharing a particular amino acid at position 80 and including the HLA-Cw*06 allele, 
was recently reported as more frequent in siblings affected by CHB than those unaffected by 
CHB (Ainsworth et al., 2017). A detailed analysis of the HLA-C alleles was not included in 
this study making comparisons difficult. However, results from our CHB family cohorts did 
not reveal any associations of the other alleles or group of alleles assigned to the HLA-C group 
with increased risk to CHB. The protective HLA-Cw*06 allele associations we found are 
therefore likely to be specific and independent of other allele associations within this 
structurally connected group of HLA-C molecules. The protective association of the HLA-
Cw*06 allele was evident across different European populations and may thus indicate that 
structural features within the peptide binding groove of this specific allelic MHC variant impact 
on disease outcome related to CHB. Hypothetically, these structural features may exclude the 
presentation of peptides needed for activation of cytotoxic T cell responses contributing to 
tissue destruction in the course of disease.   
Part of the immunopathogenesis in CHB indicated the involvement of macrophages 
driving the inflammatory processes in the fetal heart (Clancy et al., 2004) and it is suggested 
that an imbalance of the fetal immune system is involved in the initiation of the tissue 
destructive responses during pathogenesis. We validated protective HLA-DRB1*13 
associations across the Swedish and European CHB family cohorts indicating these are robust 
allelic variants that may determine fetal susceptibility to CHB. Interestingly, in European 
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populations protective DRB1*13 associations are commonly described, including many 
different systemic and organ-specific autoimmune diseases such as SLE, RA and Hashimoto´s 
thyroiditis (Bettencourt et al., 2015; Lundstrom et al., 2009; Vasconcelos et al., 2009; Zeitlin 
et al., 2008). We therefore hypothesized that the protective DRB1*13 associations for CHB 
may underlie a general mechanism of protection from inflammation shared among autoimmune 
diseases. Such a mechanism could be the result of a more proficient self-antigen presentation 
during thymic selection that would favor efficient clonal deletion of self-reactive CD4+ T cells 
by the HLA-DRB1*13 molecule (van Heemst et al., 2015). 
HLA-DRB1*04 associations with CHB could not be confirmed across both studies and 
hence, we cannot exclude this results represents a false positive association. Noticeable, for a 
number of parents, mainly Swedish, no parental genotype information was available, although 
DRB1*04 alleles were present in the CHB individuals. We could however not collect DNA 
from these parents to generate data on transmission, which potentially could confirm the 
association due to the increased number of informative pedigrees. Moreover, the DRB1*04 
allele is less common in southern Europe and hence including more families from those 
countries will probably increase the power to detect that association.  
The findings of HLA-DQA1 and -DQB1 associations with CHB, combined in the DRB1-
DQA1-DQB1 13-01:03-06:03 protective haplotype are concordant with results from a previous 
study in a Finnish cohort (Siren et al., 1999) suggesting that similar as for the DRB1 
associations, particular DQA1 and DQB1 allelic variants in complex with certain peptides elicit 
a certain type of immune recognition that may in turn impact susceptibility to CHB. In this 
context, it is interesting that DQ-restriction has been reported to be involved in the modulation 
or onset of autoimmune responses (Moustakas and Papadopoulos, 2002; Sugita et al., 1990; 
Tree et al., 2004). HLA-DQA1*01 and DQB1*06 alleles have also been described previously 
for their associations with systemic and organ-specific autoimmune diseases, like ANCA-
associated vasculitis (Gencik et al., 1999) and T1D (Kiani et al., 2015), often in combination 
with the DRB1*13 allele. 
In summary, we identified specific and discrete fetal MHC alleles that may influence 
susceptibility to CHB in addition to the maternal Ro/SSA autoantibodies. The results further 
emphasize that cytotoxic immune responses may contribute to cardiac inflammation. A likely 
interaction with CHB risk variants outside the HLA locus or variants affected by the 
proinflammatory cardiac environment (discussed in chapter 4.3.2.) may additionally influence 
disease susceptibility in predisposed individuals. 
 
 
4.3 CHB AND FACTORS WITH POTENTIAL TO INFLUENCE THE 
INTRAUTERINE ENVIRONMENT  
 
The intrauterine environment impacts on fetal health (Burton et al., 2016) and in relation to 
CHB, maternal Ro/SSA autoantibodies are the main risk factors identified that may modulate 
the fetal environment (Litsey et al., 1985; Salomonsson et al., 2005). The low recurrence rate 
for CHB despite persisting maternal autoantibodies in subsequent pregnancies however 
indicates additional factors determine fetal outcome (Ambrosi et al., 2012b; Buyon et al., 1998; 
Levesque et al., 2015). Given the relatively narrow window of the onset of CHB, defining 
factors that may influence the intrauterine environment and relate to the risk of CHB are 
relevant. In the following sections, potential CHB risk factors related to maternal 
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environmental and lifestyle factors as well as maternal autoantibody specificities will be 
described and discussed. 
 
 
4.3.1 Maternal environmental and lifestyle factors and influence to the intrauterine 
milieu 
In order to identify maternal environmental and lifestyle factors related to fetal susceptibility 
to CHB, we performed a questionnaire-based study in a population-based cohort of women 
with a positive Ro52 autoantibody serology and who had given birth to at least one child with 
CHB and may have had unaffected children.  
The overall response rate for the questionnaires was high, 89% (n=78/88), returning 
information from 81 CHB pregnancies and 108 unaffected sibling pregnancies (Paper V). 
As expected given the inclusion criteria of the study, all women were Ro52 positive with a 
considerably high proportion of Ro60 and La autoantibody positivity (Paper V).  
No differences in pregnancy outcomes were observed for the investigated maternal 
factors smoking, body mass index (BMI), and weight increase during pregnancy resulting in 
children with or without CHB (Paper V). Further, we did not observe any variances between 
medication intake and pregnancy outcomes before and during pregnancy up until gestational 
week 25 (Paper V). Of note, no protective effect for hydroxychloroquine (HCQ), previously 
suggested reducing neonatal morbidity and the recurrence risk of CHB in women diagnosed 
with SLE (Izmirly et al., 2012; Leroux et al., 2015), was detected in the study. However, the 
relatively low number of women on HCQ treatment in our study population still implements 
a potential effect for CHB development. Additionally, other medication not prescribed for 
treatment of rheumatic diseases and addressed in our study may influence pregnancy 
outcomes in the context of CHB (Paper V). 
We found that common infections during pregnancy, such as infection of the respiratory 
tracts or influenza, were associated with CHB (P=1.3x10-4, Paper V). Even though direct 
viral transmission via the placenta is rare (Irving et al., 2000), secondary effects in the offspring 
due to the maternal inflammatory state have been demonstrated and those comprise effects on 
the brain, occurrence of congenital abnormalities including the heart and may lead to preterm 
birth (Acs et al., 2005; Shi et al., 2005). This is specifically interesting taking into account the 
results from Paper II, indicating that exposure to maternal Ro/SSA autoantibodies may induce 
a proinflammatory environment in the fetus affecting the expression of genes in immune 
responses. Infectious trigger of the maternal inflammatory state contributing to the 
proinflammatory environment by e.g. increased levels of type I and II interferons, together with 
fetal susceptibilty genes may therefore decrease the threshold and precipitate CHB. 
Concordant with results from a previous study (Ambrosi et al., 2012b), we found that 
seasonal timing of pregnancy emerged as a risk factor for CHB (P=0.02, Paper V). Fetal risk 
for CHB was increased in pregnancies where the risk period (weeks 18-24) was during 
January to March and might be explained by increased frequency of infections during this 
season. Multivariate analysis supported the hypothesis that association of seasonal timing 
may be partly dependent on maternal infection. In addition to common infections, factors 
such as vitamin D levels (Ambrosi et al., 2012b) and time spend outdoors also underlie 
seasonal variation. While reports on sun exposure habits were not different among CHB and 
non-CHB pregnancies in our study, the amount of outdoor activities during daytime emerged 
as a protective factor in unaffected pregnancies and notably increased with the amount of 
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time spent outdoors (PTREND=0.01, Paper V). Interestingly, multivariate analysis disclosed 
that the association between CHB and season of birth was not independent of outdoor activity 
during daytime and hence may denote an additional important factor, apart from infections, 
underlying the association between CHB and season of birth (Paper V). Active time spent 
outdoors may be an indirect measure of several factors besides mild-to-moderate physical 
activity indicated in questionnaire examples, which per se could favorably influence the 
pregnancy. Other factors could be a reflection of the women´s general well-being during 
pregnancy or indicate increased exposure to UV light and related to higher vitamin D levels. 
In line with studies reporting an important role for vitamin D in the regulation of innate and 
adaptive immune responses and in relation to the modulation of placental inflammation 
(Lagishetty et al., 2011; Liu et al., 2011), this is an intriguing result.  
Reports of psychologically stressful events, such as the death or severe disease of a close 
relative, up until week 25 of pregnancy differed significantly with more women reporting 
such an experience during their pregnancy resulting in a child with CHB (P=0.02, Paper V). 
Indeed, there is evidence from studies showing that experiencing a life-changing event 
resulting in psychological stress may negatively influence pregnancy outcome (Adam et al., 
2013; Laszlo et al., 2013) and may hence also influence CHB pregnancy outcomes. However, 
it has to be noted that the number of women reporting such events in our study was low and 
thus confirmation from studies including lager cohorts is needed to assess psychological 
stress as a potential risk factor in the context of CHB. 
In summary, we have shown that certain maternal environmental and lifestyle factors 
with the potential to modulate the intrauterine environment associated with different 
pregnancy outcomes related to CHB in presence of Ro/SSA autoantibodies. However, 
prospective studies will be needed to confirm these data. 
 
 
4.3.2 Intrauterine exposure to maternal anti-auxilin-2 autoantibodies 
Among the anti-SSA/Ro52 maternal autoantibodies, anti-Ro52/p200 antibodies feature the 
most antigenic epitope within the Ro52 protein and associate with an increased risk for fetal 
CHB in relation to anti-p200 antibody presence and levels (Ottosson et al., 2005; 
Salomonsson et al., 2002; Strandberg et al., 2008; Tonello et al., 2016). It has been shown 
that anti-SSA/Ro52 and anti-Ro52/p200 antibodies may cross-react with targets in the fetal 
heart; however, the proportion of these cross-reactive autoantibodies specificities in positive 
tested sera from mothers with CHB-affected children were considerable low (Buyon et al., 
2002; Karnabi et al., 2010; Qu et al., 2005; Qu et al., 2001; Strandberg et al., 2013). This 
indicates that maternal antibody reactivity to one or more additional cross-targets may exist, 
and these specificities are potentially more explanatory for fetal disease pathogenesis than the 
previously described cross-reactive autoantibody specificities. We therefore aimed to identify 
novel targets of anti-Ro52/p200-specific antibodies using a broad proteome library screen 
and investigate their clinical relevance in CHB. 
In line with the cross-target hypothesis, in vivo transfer of monoclonal antibodies specific 
for the p200 region of Ro52 into pregnant mice, led to signs of first degree AV block in the 
pups even in absence of the Ro52 protein. Signs of AV block were not observed in mouse 
pups exposed to anti-Ro52 antibodies specific to the C-terminal region of Ro52 (Paper VI). 
This is concordant with previous studies showing anti-Ro52/p200 antibodies, but not other 
Ro52-specificites, can induce AV block in rat pups after transfer (Strandberg et al., 2010).  
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With a peptide screen covering the human proteome we found that anti-Ro52/p200 
antibodies cross-react with peptides sharing either one of two minimal epitopes “YSDF” 
(Tyr-Ser-Asp-Phe) or “YSNF” (Tyr-Ser-Asn-Phe) (Paper VI). Proteome mapping of those 
peptide sequences led to the identification of seven potential cross-targets for CHB 
recognized by Ro52/p200 but no other Ro52 specific antibodies, among those auxilin-2 and 
thyroglobulin (Paper VI). Interestingly, auxilin-2/GAK (Cyclin G Associated Kinase) is a 
homologue to auxilin-1/DNAJC6, which we identified as a novel fetal susceptibility gene for 
CHB (Paper I). Despite their relatively high sequence homology, the “YSNF” epitope maps 
to a protein kinase domain of auxilin-2, not present in auxilin-1 (Paper VI).  
We found that 22.4% of the antiRo52/p200 positive mothers who had given birth to a 
child with CHB displayed cross-reactivity to auxilin-2, which was significantly higher 
compared to control sera (P<0.001, Paper VI). Interestingly, high p200 titers correlated with 
higher anti-auxilin-2 reactivity, showing that reactivity towards auxilin-2 may occur in an 
anti-p200 level-dependent manner (Paper VI). The proportion of maternal anti-Ro52/p200 
autoantibodies specific for auxilin-2 was higher in our study compared to other studies 
showing 14 and 16% of the maternal CHB sera are positive for the Ro/SSA autoantibodies 
cross-specificities in maternal CHB sera (Buyon et al., 2002; Karnabi et al., 2010). 
Nonetheless, cross-reactive auxilin-2 antibody proportions are still far below 100%. This 
indicates other, yet unknown and clinically more relevant cross-targets for anti-Ro52/p200 
antibodies may exist. This hypothesis is supported by a recent study demonstrating that 
different fine specificities within the Ro52/p200 region are found in sera from mothers having 
children with CHB (Hoxha et al., 2016). 
Risk carrier frequencies of auxilin-1, the functional homologue of auxilin-2 and a novel 
fetal susceptibility gene for CHB (Paper I), were not associated with abundance or titers of 
maternal auxilin-2 cross-reactivity in children affected by CHB (Paper VI) suggestive of 
both risk factors acting in independent pathways influencing the course of disease. 
Interestingly, we found that ventricular septal defects (VSD) associated with maternal 
anti-auxilin-2 cross-reactivity in individuals affected by CHB (P=0.02, Paper VI) indicating 
this specific cardiac manifestation of CHB may relate to maternal anti-auxilin-2 antibodies.  
Collectively, this study suggests that the intrauterine exposure to maternal anti-auxilin-2 
autoantibodies may contribute to susceptibility to CHB, however in a clinically minor manner. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
In this thesis, fetal genetic variants and factors influencing the intrauterine environment and 
their relevance for fetal susceptibility to CHB were investigated. 
We identified distinct cellular pathways to be associated with CHB and further explored 
genes in these pathways in relation to the fetal cardiac disease. In one of the CHB-associated 
pathways, vesicular transport, we identified and functionally characterized auxilin as a novel 
fetal susceptibility gene for CHB affecting cardiac excitation-contraction coupling. In 
addition, we have shown that several other variants affecting genes with a function in 
vesicular or transmembrane transport and cardiac contraction were associated with CHB. 
Thus, fetal genetic variants involved in cellular processes sustaining cardiac excitation-
contraction coupling may determine the clinical outcome in Ro/SSA autoantibody exposed 
fetuses. 
We furthermore identified several CHB-associated variants affecting genes with a 
function in immune responses. We have shown that a proinflammatory environment, related 
to the maternal Ro/SSA autoantibodies or interferon alpha, affects the expression of these 
genes in cardiomyocytes and PBMCs. Moreover, we found several distinct HLA alleles to 
be associated with CHB. Collectively, the fetal genetic variants with assigned function in 
immune responses identified are likely to interfere with the inflammatory and tissue 
destructive processes during CHB pathogenesis. Furthermore, the interaction of these fetal 
genetic variants with the proinflammatory intrauterine environment determined by the 
maternal Ro/SSA autoantibodies may additionally influence fetal susceptibility to CHB. 
We have shown that infections, seasonal timing of pregnancy, outdoor activity and 
psychological stress are associated with CHB and effects of these factors on the intrauterine 
environment may additionally influence fetal susceptibility to CHB in Ro/SSA positive 
pregnancies. Finally, we have shown the existence of cross-targets for the maternal anti-
Ro52/p200 antibodies and that fetal intrauterine exposure to these maternal autoantibody 
specificities may influence the clinical outcomes of disease. 
Further studies are needed to confirm the relevance of each of these factors in the context 
of CHB pathogenesis, and several of the identified factors should be possible to explore in 
terms of prevention and treatment of the disease. In line with this, prospective studies 
combining clinical parameters on fetal conduction disturbances and factors identified to 
determine fetal susceptibility will further elucidate crucial clues to CHB pathology and 
treatment options. 
 
Taken together, the results from our studies expand the current model and understanding of 
CHB pathogenesis. In addition to the pathogenic effects of the maternal Ro/SSA 
autoantibodies, the overall fetal susceptibility to CHB and degree of severity will depend on 
the combination of genetic risk variants, their functional consequences, and their interaction 
with intrauterine risk factors (Figure 9). 
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Figure 9. Risk factors for autoimmune-mediated CHB.  
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